SuPAR predicts postoperative complications and mortality in patients with asymptomatic aortic stenosis by Hodges, Gethin W et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
SuPAR predicts postoperative complications and mortality in patients with
asymptomatic aortic stenosis
Hodges, Gethin W; Bang, Casper N; Eugen-Olsen, Jesper; Olsen, Michael H; Boman, Kurt;
Ray, Simon; Kesäniemi, Antero Y; Jeppesen, Jørgen L; Wachtell, Kristian
Published in:
Open Heart
DOI:
10.1136/openhrt-2017-000743
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Hodges, G. W., Bang, C. N., Eugen-Olsen, J., Olsen, M. H., Boman, K., Ray, S., ... Wachtell, K. (2018). SuPAR
predicts postoperative complications and mortality in patients with asymptomatic aortic stenosis. Open Heart,
5(1), e000743. https://doi.org/10.1136/openhrt-2017-000743
Download date: 03. Feb. 2020
Open Access 
  1Hodges GW, et al. Open Heart 2018;5:e000743. doi:10.1136/openhrt-2017-000743
To cite: Hodges GW, Bang CN, 
Eugen-Olsen J, et al. SuPAR 
predicts postoperative 
complications and mortality in 
patients with asymptomatic 
aortic stenosis. Open Heart 
2018;5:e000743. doi:10.1136/
openhrt-2017-000743
Received 31 October 2017
Revised 30 November 2017
Accepted 20 December 2017
For numbered affiliations see 
end of article.
Correspondence to
Dr Gethin W Hodges;  gethin. 
william. hodges. 02@ regionh. dk
SuPAR predicts postoperative 
complications and mortality in patients 
with asymptomatic aortic stenosis
Gethin W Hodges,1 Casper N Bang,2 Jesper Eugen-Olsen,3 Michael H Olsen,4,5 
Kurt Boman,6 Simon Ray,7 Antero Y Kesäniemi,8 Jørgen L Jeppesen,1 
Kristian Wachtell9
Valvular heart disease
AbstrAct
Background We evaluated whether early measurement of 
soluble urokinase plasminogen activator receptor (suPAR) 
could predict future risk of postoperative complications in 
initially asymptomatic patients with mild-moderate aortic 
stenosis (AS) undergoing aortic valve replacement (AVR) 
surgery.
Methods Baseline plasma suPAR levels were available in 
411 patients who underwent AVR surgery during follow-
up in the Simvastatin and Ezetimibe in Aortic Stenosis 
(SEAS) study. Cox analyses were used to evaluate suPAR in 
relation to all-cause mortality and the composite endpoint 
of postoperative complications (all-cause mortality, 
congestive heart failure, stroke and renal impairment) 
occurring in the 30-day postoperative period.
Results Patients with initially higher levels of suPAR 
were at increased risk of postoperative mortality with a 
HR of 3.5 (95% CI 1.4 to 9.0, P=0.008) and postoperative 
complications with a HR of 2.7 (95% CI 1.5 to 5.1, 
P=0.002), per doubling in suPAR. After adjusting for the 
European System for Cardiac Operative Risk Evaluation or 
Society of Thoracic Surgeons risk score, suPAR remained 
associated with postoperative mortality with a HR 3.2 
(95% CI 1.2 to 8.6, P=0.025) and 2.7 (95% CI 1.0 to 7.8, 
P=0.061); and postoperative complications with a HR of 
2.5 (95% CI 1.3 to 5.0, P=0.007) and 2.4 (95% CI 1.2 to 
4.8, P=0.011), respectively.
Conclusion Higher baseline suPAR levels are associated 
with an increased risk for postoperative complications and 
mortality in patients with mild-moderate, asymptomatic AS 
undergoing later AVR surgery. Further validation in other 
subsets of AS individuals are warranted.
Trial registration number NCT00092677; Post-results.
InTRoduCTIon
Soluble urokinase plasminogen activator 
receptor (suPAR) is a biomarker of inflam-
mation that is associated with adverse prog-
nosis in a range of diseases, including cancer, 
cardiovascular, renal and liver disease.1–4 
SuPAR appears to reflect a chronic ather-
osclerotic disease burden and subclinical 
organ damage1 and was recently shown to 
predict cardiovascular events and mortality in 
individuals with asymptomatic aortic stenosis 
(AS).5 Furthermore, suPAR has been shown 
to be predictive of acute kidney injury in 
patients undergoing cardiac surgery, even in 
patients without pre-existing chronic kidney 
disease.6 
In apparently asymptomatic patients with 
AS, the potential benefits of an aortic valve 
replacement (AVR) procedure must be 
weighed against the risks of surgery.7 8 Vali-
dated risk stratification tools such as the 
European System for Cardiac Operative Risk 
Evaluation (EuroSCORE) II and Society of 
Thoracic Surgeons (STS) score are useful in 
predicting early 30-day mortality, and more 
recently, the prognostic utility of alternative 
scoring systems incorporating inflammatory 
markers has been demonstrated.9–14
We, therefore, hypothesised that suPAR 
would be of prognostic value in predicting 
early (30 day) postoperative AVR mortality 
and complications in patients with mild-mod-
erate, asymptomatic AS and furthermore 
would enhance the performance of the Euro-
SCORE II and STS risk-score models.
Key questions
What is already known about this subject?
 ► The inflammatory marker soluble urokinase 
plasminogen activator receptor (suPAR) is of 
prognostic value in a range of cardiovascular 
diseases, including in initially asymptomatic 
patients with mild-moderate aortic stenosis. 
What does this study add?
 ► Patients with initially higher levels 
of suPAR undergoing aortic valve 
replacement  surgery are at increased risk of 
postoperative complications and mortality.
How might this impact on clinical practice?
 ► SuPAR appears to provide additive prognostic 
information beyond the European System for 
Cardiac Operative Risk Evaluation II and Society 
of Thoracic Surgeons score; however, further 
validation in other patient groups is needed.
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MeTHods
study design and patient population
This study stems from the larger Simvastatin and 
Ezetimibe in Aortic Stenosis (SEAS) study, which eval-
uated the potential of lipid-lowering drug treatment to 
minimise aortic valve events, cardiovascular disease and 
death. The baseline characteristics and design protocol 
for the main SEAS study have been published in detail 
elsewhere.15 In brief, 1873 patients with mild-moderate 
AS, as determined by Doppler ultrasound (aortic peak 
velocity ≥2.5 and ≤4.0 m/s), received treatment with 
either simvastatin 40 mg and ezetimibe 10 mg or placebo 
over a 4.3-year period. The original results showed that 
lipid-lowering treatment was not associated with a reduc-
tion in the primary and combined endpoint; however, a 
22% reduction in ischaemic events was observed.15 In this 
substudy, a total of 545 patients underwent conventional 
AVR surgery during this follow-up period (repeat oper-
ations were excluded). Plasma suPAR levels at baseline 
were available in 411 of these patients. The median time 
from baseline suPAR measurement to AVR surgery was 
994 days (IQR 637–1270 days). A postoperative follow-up 
period of 30 days was chosen to reflect the standard 
used by the EuroSCORE II and STS score. In total, 134 
patients were excluded due to missing values (assumed 
to be missing at random). The excluded patients did not 
differ significantly from the included participants with 
respect to important aspects, including age, gender and 
severity of AS (P value all >0.2).
Biochemical analysis
Plasma (EDTA) suPAR was analysed using a commercial 
CE/IVD (Conformité Européene /In Vitro Diagnostics) 
approved ELISA assay (suPARnostic, ViroGates, Copen-
hagen, Denmark). The assay was validated to measure 
suPAR levels between 0.6 and 22 ng/mL. Samples were 
analysed at the same time point and in the same batch, 
with an interassay coefficient of variation of 9.9%. SuPAR 
has been shown to be without substantial circadian varia-
tion, and the biomarker is stable in frozen samples.16
statistical analysis
Data were analysed using IBM SPSS software V.24 and 
RStudio software V.0.98.1102 (RStudio). Continuous vari-
ables are presented as means±SD deviation for normally 
distributed values, median and IQR for skewed variables 
and numbers and percentages for categorical variables. 
Baseline suPAR was not associated with treatment allo-
cation. Hence, the placebo and treatment groups were 
combined in a single cohort for analysis.
Non-normally distributed variables (including suPAR, 
EuroSCORE II and the STS risk score) were log2-trans-
formed before analysis.
We evaluated the outcomes of AVR postoperative 
(all-cause) mortality and postoperative complications 
(defined as all-cause mortality, congestive heart failure, 
non-haemorrhagic or haemorrhagic stroke and renal 
impairment), occurring within the 30-day postoperative 
period. Cox analysis was performed for suPAR evaluated 
alongside the preoperative EuroSCORE II and the STS 
score. No further adjustment was made for confounders 
as both the EuroSCORE II and STS score are validated 
systems, which were deemed to have included relevant 
key variables. A further sensitivity analysis was performed 
incorporating the most recent preoperative suPAR values, 
which did not substantially alter the results.
The proportional hazards assumption for Cox’s 
models was robust, as verified with plots of Schoen-
feld residuals. The ability of the Cox models to predict 
adverse events was evaluated using standard metrics: 
C-statistic, continuous net reclassification index (NRI) 
and integrated discrimination index (IDI).
Calculation of eurosCoRe II and sTs risk score
The calculation of EuroSCORE II and STS risk score 
used variables and definitions previously reported 
(online STS risk score calculator, V.2.81; http:// riskcalc. 
sts. org).9–11 The preoperative scores were calculated as 
part of a post hoc analysis using the most recent data 
available for each patient and included the following 
assumptions: New York Heart Association (NYHA) clas-
sification of heart failure was defined using established 
criteria, and though NYHA class was not explicitly 
recorded for each patient, it was inferred from recorded 
data (heart failure in conjunction with severity of dysp-
noea).17 The insulin-dependent diabetes risk factor was 
assumed to be zero, given that pre-existing diabetes was 
an exclusion criterion in the SEAS study (four patients 
developed new-onset type 2 diabetes before AVR surgery 
and were assumed to be non-insulin dependent). The 
‘poor mobility’ variable was assumed to be zero, as it 
was expected that the number of patients with poor 
mobility would be low in a study population free from 
major comorbidities at the onset of the study. Critical 
preoperative state was estimated based on documented 
arrhythmia (ventricular tachycardia or ventricular 
fibrillation), need for inotropes (one patient experi-
enced a ‘severe’ third degree atrioventricular block, 
presumed to require inotropes) or acute renal failure 
(documented severe oliguria) occurring within a 3-day 
preoperative period (data was missing on preoperative 
aborted sudden death, cardiac massage, assisted venti-
lation, intra-aortic balloon or ventricular assist devices). 
Data on left main disease and immunosuppression 
treatment was unavailable for the STS score. All proce-
dures were assumed to be elective. All  patients  gave 
written informed consent.
ResulTs
Baseline characteristics of the total study population (and 
subdivided by postoperative complications) are shown in 
table 1. During the 4.3-year follow-up period, for the 411 
AVR procedures included in this study, 32 AVR postoper-
ative complication events were recorded (including 14 
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all-cause mortalities, eight strokes, eight incidences of renal 
failure and four incidences of congestive heart failure).
The ability of suPAR to predict postoperative mortality 
and complications, in relation to the EuroSCORE II and 
STS risk score models, is shown in table 2.
In univariate analysis, suPAR and STS score were both 
significantly associated with postoperative mortality and 
postoperative complications, while EuroSCORE II was 
only weakly associated.
Table 1 Baseline characteristics of the total study population and subdivided by postoperative complications
Variable Total (n=411)
With postoperative 
complications (n=32)
Without postoperative 
complications (n=379)
Demographics
  Age (years) 67±9 69±10 67±9
  Female sex (%) 38 22 39
Haemodynamic parameters
  Systolic BP (mm Hg) 143±21 137±21 144±21
  Diastolic BP (mm Hg) 82±11 81±12 82±11
  LVEF (%) 65±9 63±9 65±9
Cardiovascular risk factors
  Hypertension (%) 100 100 100
  Current smoker (%) 21 28 20
  BMI (kg/m2) 27±4 28±5 27±4
Laboratory values
  SuPAR (ng/mL) 2.6 (2.1, 3.3) 3.0 (2.5, 3.9) 2.6 (2.1, 3.2)
  Glucose (mmol/L) 5.2 (4.9, 5.6) 5.3 (4.9, 6.0) 5.2 (4.8, 5.6)
  CRP (mg/L) 2.4 (1.0, 4.9) 1.9 (1.0, 5.5) 2.5 (1.0, 4.9)
  WBC (109/L) 6.0±1.6 5.7±1.4 6.1±1.6
  Total cholesterol (mmol/L) 5.7±1.0 5.3±0.8 5.8±1.0
  LDL (mmol/L) 3.5±0.9 3.2±0.8 3.6±0.9
  HDL (mmol/L) 1.6±0.4 1.5±0.4 1.6±0.4
  Triglycerides (mmol/L) 1.2 (0.9, 1.7) 1.2 (0.9, 1.4) 1.2 (0.9, 1.7)
  Creatinine (μmol/L) 94±16 98±14 93±16
BMI, body mass index; BP, blood pressure; CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LVEF, left 
ventricular ejection fraction; suPAR, soluble urokinase plasminogen activator receptor; WBC, white blood cells.
Table 2 Cox regression model predictions for postoperative mortality and CEP of postoperative complications
Model
Postoperative mortality, HR 
(95% CI) P value
CEP of postoperative 
complications, HR (95% CI) P value
Univariate
  Log2-suPAR (ng/mL) 3.5 (1.4 to 9.0) 0.008 2.7 (1.5 to 5.1) 0.002
  Log2-EuroSCORE II 1.8 (0.9 to 3.7) 0.113 1.6 (0.9 to 2.6) 0.085
  Log2-STS score 2.4 (1.2 to 4.8) 0.013 1.7 (1.0 to 2.7) 0.032
suPAR/EuroSCORE II
  Log2-suPAR (ng/mL) 3.2 (1.2 to 8.6) 0.025 2.5 (1.3 to 5.0) 0.007
  Log2-EuroSCORE II 1.3 (0.6 to 2.8) 0.492 1.2 (0.7 to 2.0) 0.552
suPAR/STS score
  Log2-suPAR (ng/mL) 2.7 (1.0 to 7.8) 0.061 2.4 (1.2 to 4.8) 0.011
  Log2-STS score 1.9 (0.9 to 4.0) 0.104 1.3 (0.8 to 2.2) 0.263
EuroSCORE II, European System for Cardiac Operative Risk Evaluation II; CEP, composite endpoint of postoperative complications (all-cause 
mortality, congestive heart failure, non-haemorrhagic or haemorrhagic stroke and renal impairment) occurring within the 30-day postoperative 
period; STS, Society of Thoracic Surgeons; suPAR, soluble urokinase plasminogen activator receptor.
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After mutually adjusting for suPAR and EuroSCORE II 
or STS score, suPAR remained associated with postopera-
tive mortality and postoperative complications, although 
for the model containing suPAR and the STS score, the 
association of suPAR with postoperative mortality was of 
borderline significance.
discrimination tests
The baseline models (using EuroSCORE II/STS score 
alone) showed poor discrimination in predicting postoper-
ative mortality and postoperative complications; however, 
inclusion of suPAR resulted in marginal (but non-signif-
icant) improvements in discrimination (as measured by 
the C-statistic) over the standard EuroSCORE II and STS 
score models, which translated into an improvement in 
the NRI and IDI indices (see table 3).
dIsCussIon
In initially asymptomatic patients with mild-moderate 
AS, we found that early detection of higher suPAR levels 
was of prognostic value in predicting 30-day postopera-
tive mortality and postoperative complications after AVR, 
performed during a 4.3-year follow-up, and after adjusting 
for the EuroSCORE II or STS score. Inclusion of suPAR 
in the prediction models for postoperative complications 
or mortality, yielded significant improvements in the 
NRI, compared with the standard EuroSCORE II or STS 
score models. However, the discriminative power of the 
models was only modest.
Despite technological advances, standard AVR surgery 
remains a major procedure with the potential for several 
early complications, including valve related, cardiac 
non-valve related and non-cardiac events. The ability 
to risk-stratify individuals undergoing surgery and to 
recognise and treat potential complications is of clinical 
value, and efforts to incorporate various biomarkers in 
risk-stratification systems has met with some success.14 
SuPAR has potential value as a biomarker due to its high 
stability in serum samples and limited circadian varia-
tion in plasma concentrations.16 At present, it remains 
unclear whether suPAR is merely a passive biomarker or 
a pathogenic agent. It has been suggested that suPAR is 
a causative factor in the development of chronic kidney 
disease and focal segmental glomerular sclerosis, 
although there is ongoing debate in the literature.2 18 19 
Higher plasma suPAR levels were demonstrated to be 
an early independent predictor of progressive renal 
dysfunction in patients with cardiovascular disease and 
normal kidney function, suggesting that suPAR may 
be a more sensitive marker of chronic kidney disease 
than traditional measures such as decline in esti-
mated glomerular filtration rate or proteinuria.3 This 
is supported by a recent study, where suPAR predicted 
acute kidney injury in patients undergoing cardiac 
surgery, even in patients without pre-existing chronic 
kidney disease.6 Patients with chronic kidney disease 
are at increased risk of cardiovascular disease and 
death and are more vulnerable to acute kidney injury 
in the perioperative period.20 21 Hence, we can specu-
late that early detection of elevated suPAR may identify 
patients with subclinical renal disease who presumably 
could benefit from closer monitoring to reduce the risk 
of complications. However, far from being limited to 
renal disease, suPAR has been associated with adverse 
outcomes in many studies and appears to reflect 
immune activation and inflammation in several disease 
states, including patients with cancer, critically ill 
patients and cardiovascular and liver disease.1–4 SuPAR 
has been implicated in many of the pathways involved 
in atherosclerosis, including the plasminogen acti-
vating pathway, inflammation, modulation of cell adhe-
sion, migration and proliferation.22 Research suggests 
that suPAR represents a chronic atherosclerotic disease 
burden and subclinical organ damage, and suPAR has 
Table 3 Model performance (baseline univariate) and including suPAR for postoperative mortality and postoperative 
complications
Model C-statistic
P value for 
difference NRI P value IDI P value
Postoperative mortality
  Log2-EuroSCORE II 0.55 (0.35–0.74)
  Log2-EuroSCORE II* 0.69 (0.50–0.89) 0.103 38% 0.048 0.018 0.034
  Log2-STS score 0.66 (0.43–0.89)
  Log2-STS score* 0.71 (0.51–0.91) 0.056 29% 0.088 0.019 0.032
Postoperative complications
  Log2-EuroSCORE II 0.58 (0.44–0.72)
  Log2-EuroSCORE II* 0.68 (0.56–0.81) 0.085 30% 0.024 0.022 0.012
  Log2-STS score 0.61 (0.48–0.73)
  Log2-STS score* 0.67 (0.56–0.79) 0.058 36% 0.008 0.021 0.012
*Baseline model including suPAR.
EuroSCORE II,  European System for Cardiac Operative Risk Evaluation  II; IDI, integrated discrimination index; NRI, net reclassification 
index; STS, Society of Thoracic Surgeons; suPAR, soluble urokinase plasminogen activator receptor.
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been demonstrated to be an independent predictor of 
incident cardiovascular disease and mortality in both 
‘healthy’ individuals and in patients with established 
or suspected coronary artery disease.23 24 Our results 
support the hypothesis that early detection of elevated 
suPAR levels may help identify a vulnerable patient, 
who is more prone to complications in the postop-
erative period. However, a precise cut-off for suPAR 
has yet to be established; hence, further research is 
required before suPAR can be adopted into current 
practice. Several limitations should be noted when 
interpreting these results. It is important to note that 
postoperative mortality and complications depend on 
both patient risk factors and care delivery factors, and 
technical problems during surgery as well as human 
and institutional factors in postoperative care, which 
have not been considered in our analysis.25 The SEAS 
study excluded patients with significant comorbidities 
(some of which are risk factors for AS progression); 
hence, it does not adequately represent the general 
population of patients with AS. A key limitation in this 
study is that preoperative suPAR levels were not explic-
itly recorded in the original study and brain natriuretic 
peptide measurements were not available. Preoperative 
EuroSCORE II and STS scores were estimated based on 
the most recent biochemistry data and involved several 
assumptions on the classification of NYHA class, insu-
lin-dependent diabetes, critical perioperative state, 
pulmonary hypertension, poor mobility and urgency 
of the operation (see the Methods section). Missing 
data is likely to result in an underestimation of the true 
EuroSCORE II and STS scores for some patients. This 
study was a post hoc study, non-prespecified with the 
obvious limitations this carries.
ConClusIons
SuPAR measured in patients with mild-moderate AS 
predicts postoperative mortality and complications in 
relation to later AVR surgery and may provide useful 
additive prognostic information to enable risk stratifi-
cation of these patients. However, further prospective 
studies in other subsets of asymptomatic patients with AS 
are warranted before suPAR can be recommended for 
inclusion in risk prediction models for these patients.
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